Skip to content

aTyr Pharma ATYR Other Receivables

Other Receivables at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$267K-92.6%

Other financials

Income statement

See full
Revenue-
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%
EPS (diluted)-$0.11+35.3%

Balance sheet

See full
Cash & equivalents$10.0M-3.4%
Total debt$12.3M-9.2%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K
Free cash flow-$12.7M+17.9%

Valuation

See full
Market cap$54.88M-88.2%
Enterprise value$57.17M
P/S288.8×

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-105.3%+50.6pp
Debt / equity0.2×0.0×
Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:OtherReceivablesNetCurrent.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's other receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is aTyr Pharma's other receivables?
aTyr Pharma (ATYR) reported other receivables of $477K in Q1 2026.
How has aTyr Pharma's other receivables changed year-over-year?
aTyr Pharma's other receivables decreased by 51.7% year-over-year, from $988K to $477K.
What is the long-term trend for aTyr Pharma's other receivables?
Over 5 years (2020 to 2025), aTyr Pharma's other receivables has grown at a -15.6% compound annual growth rate (CAGR), from $2.04M to $873K.
What does other receivables mean?
This represents miscellaneous claims for cash or other assets not classified under standard trade accounts receivable. It often includes tax refunds, interest receivables, or non-core operational claims. Monitoring this helps identify potential hidden liquidity issues or delays in cash conversion.